Systemic fungal infections in neonates

• Main Authors: Rao S, Ali U
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2005-01-01
• Series: Journal of Postgraduate Medicine
• Subjects: Systemic fungal infection; neonataes; Fungisome; Amphotericin
• Online Access: http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=5;spage=27;epage=29;aulast=Rao

Advances in neonatal management have led to considerable improvement in newborn survival. However, early (< 72 hours) and late (>72hours) onset systemic infections, both bacterial and fungal, remain a devastating complication and an important cause of morbidity and mortality in these babies. Most neonatal fungal infections are due to Candida species, particularly Candida albicans. The sources of candidiasis in NICU are often endogenous following colonization of the babies with fungi. About 10&#x0025; of these babies get colonized in first week of life and up to 64&#x0025; babies get colonized by 4 weeks of hospital stay. Disseminated candidiasis presents like bacterial sepsis and can involve multiple organs such as the kidneys, brain, eye, liver, spleen, bone, joints, meninges and heart. Confirming the diagnosis by laboratory tests is difficult and a high index of suspicion is required. The diagnosis of fungemia can be made definitely only by recovering the organism from blood or other sterile bodily fluid. Amphotericin B continues to be the mainstay of therapy for systemic fungal infections but its use is limited by the risks of nephrotoxicity and hypokalemia. Newer formulations of amphotericin B, namely the liposomal and the lipid complex forms, have recently become available and have been reported to have lesser toxicity. More recently Indian liposomal Amphotericin B derived from neutral lipids (L-Amp -LRC-1) has shown good response with less toxicity. A clinical trial with this preparation has shown to be safe and efficacious in neonatal fungal infections. Compared to other liposomal preparations, L-Amp-LRC-1 is effective at lower dose and is less expensive drug for the treatment of neonatal candidiasis.